Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies

Tuesday, September 05, 2023
NIH Default Logo

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced preliminary analyses and positive biomarker data from Biohaven's exploratory Phase 1 electroencephalogram (EEG) biomarker study, which was presented to epilepsy key opinion leaders at an off-site meeting held during the International Epilepsy Conference 2023 in Dublin, Ireland. The preliminary study results confirm central nervous system (CNS) activity of BHV-7000 at projected therapeutic concentrations, dose-dependent and time-dependent changes in EEG spectral power and are consistent with EEG effects observed with other antiseizure medications (ASMs) approved for the treatment of epilepsy. Biohaven's Phase 3 program in focal epilepsy is anticipated to begin before the end of 2023.

Read full article.